This matrix-based strategy was used to screen ABC-DLBCL cell lines for sensitivity to the BCR inhibitor ibrutinib in combination with nearly 500 established or investigational anti-cancer compounds [233]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.